Distribuzione geografica
Continente #
NA - Nord America 1.554
EU - Europa 339
AS - Asia 108
AF - Africa 13
SA - Sud America 5
OC - Oceania 1
Totale 2.020
Nazione #
US - Stati Uniti d'America 1.540
IT - Italia 121
FR - Francia 96
CN - Cina 74
DE - Germania 34
CA - Canada 14
CZ - Repubblica Ceca 14
IN - India 12
ZA - Sudafrica 12
FI - Finlandia 11
GB - Regno Unito 9
UA - Ucraina 9
IE - Irlanda 8
RU - Federazione Russa 8
HK - Hong Kong 7
JP - Giappone 7
ES - Italia 6
NL - Olanda 6
SE - Svezia 4
CL - Cile 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
BR - Brasile 2
DK - Danimarca 2
GR - Grecia 2
LT - Lituania 2
PL - Polonia 2
SA - Arabia Saudita 2
AU - Australia 1
BE - Belgio 1
CH - Svizzera 1
ID - Indonesia 1
IL - Israele 1
KH - Cambogia 1
KR - Corea 1
LV - Lettonia 1
SN - Senegal 1
Totale 2.020
Città #
Fairfield 196
Ashburn 137
Houston 121
Santa Cruz 102
Seattle 100
Woodbridge 82
Padova 79
Buffalo 78
Cambridge 65
Wilmington 55
Beijing 48
Ann Arbor 40
Des Moines 38
Chicago 34
San Diego 22
Paris 18
New York 15
Boardman 14
Las Vegas 12
Los Angeles 12
Helsinki 11
Henderson 11
Muizenberg 11
Phoenix 9
San Francisco 9
Dublin 8
Ottawa 7
Riva 7
San Donà Di Piave 7
University Park 7
Clearwater 6
Lake Forest 6
San Jose 6
Dallas 5
Redmond 5
Auburn 4
Barcelona 4
Belluno 4
Chennai 4
Easton 4
Herndon 4
Saint Petersburg 4
Shanghai 4
Ulm 4
Wuhan 4
Atlanta 3
Bengaluru 3
Castelcovati 3
Cedar Knolls 3
Council Bluffs 3
Denver 3
Dieppe 3
Kirkland 3
Lombard 3
Tokyo 3
Toronto 3
Verona 3
Brendola 2
Central 2
Créteil 2
Frankfurt am Main 2
Ha Kwai Chung 2
Hangzhou 2
Honolulu 2
Jacksonville 2
Kyoto 2
Madison 2
Milan 2
Milpitas 2
Mumbai 2
Parlin 2
Parma 2
Portland 2
Recife 2
Saint Louis 2
Santa Clara 2
Seville 2
Trieste 2
Uppsala 2
Wanchai 2
Warsaw 2
Wuhu 2
Ahmedabad 1
Altlußheim 1
Amsterdam 1
Apex 1
Aprilia 1
Boulder 1
Brussels 1
Büdelsdorf 1
Campobasso 1
Caprino Veronese 1
Columbus 1
Condat-sur-Vienne 1
Copenhagen 1
Crugers 1
Dakar 1
Delhi 1
Dulles 1
Edinburgh 1
Totale 1.527
Nome #
Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals, file e14fb26a-115f-3de1-e053-1705fe0ac030 173
STAT3 mutation impacts biological and clinical features of T-LGL leukemia, file e14fb26a-0b15-3de1-e053-1705fe0ac030 162
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases, file e14fb26a-54a7-3de1-e053-1705fe0ac030 135
Role of miR-15a/miR-16-1 and TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia, file e14fb26a-0d5c-3de1-e053-1705fe0ac030 131
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival, file e14fb268-c45b-3de1-e053-1705fe0ac030 125
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: Data from the prospective, multicenter phase-II CLL-009 trial, file e14fb268-90cd-3de1-e053-1705fe0ac030 123
Hexokinase 2 displacement from mitochondria‐associated membranes prompts Ca 2+ ‐dependent death of cancer cells, file e14fb26c-bee6-3de1-e053-1705fe0ac030 123
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells, file e14fb269-060c-3de1-e053-1705fe0ac030 121
Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma, file e14fb26c-9cf6-3de1-e053-1705fe0ac030 108
The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells, file e14fb268-be07-3de1-e053-1705fe0ac030 104
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment, file e14fb26c-b00a-3de1-e053-1705fe0ac030 81
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy, file e14fb26d-5296-3de1-e053-1705fe0ac030 63
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naïve chronic lymphocytic leukemia, file e14fb26c-960c-3de1-e053-1705fe0ac030 57
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact, file e14fb26f-8462-3de1-e053-1705fe0ac030 54
Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells, file e14fb26a-2040-3de1-e053-1705fe0ac030 49
p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape, file e14fb26c-aa0d-3de1-e053-1705fe0ac030 47
Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A., file e14fb26f-96b5-3de1-e053-1705fe0ac030 40
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations, file e14fb26e-8163-3de1-e053-1705fe0ac030 39
Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia., file e14fb268-2cb5-3de1-e053-1705fe0ac030 29
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia, file e14fb26f-c351-3de1-e053-1705fe0ac030 17
CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis, file e14fb26f-ad0f-3de1-e053-1705fe0ac030 14
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation, file aaf97301-4e55-41ac-9882-55c2bbada3e2 12
Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma, file d6c9fd8e-1502-4765-9914-2c02188633d7 11
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL), file 84a7338a-70b8-4567-a75e-9fa4b34371ef 10
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases, file 9b3cbfb3-3721-4aff-b62c-9881031ace9e 10
[18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases, file be7c8f1f-c156-4a8a-8270-408e14a71f5c 10
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients., file ccb0f900-3a13-424d-b6a4-e86c01bf471a 10
Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes, file e14fb267-927b-3de1-e053-1705fe0ac030 10
Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations, file c6955adf-1a8b-4b31-9e94-81141158156e 9
Selection of T lymphocyte bearing limited TCR-V beta regions in the lung of hypersensitivity pneumonitis and sarcoidosis., file e14fb267-6164-3de1-e053-1705fe0ac030 9
Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells, file e14fb267-aa92-3de1-e053-1705fe0ac030 9
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients., file e14fb269-5ca4-3de1-e053-1705fe0ac030 9
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies, file e14fb26e-7bdd-3de1-e053-1705fe0ac030 9
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma, file e14fb26f-94c8-3de1-e053-1705fe0ac030 9
Treating Secondary Antibody Deficiency in Patients with Haematological Malignancy: European Expert Consensus, file 42c09162-30a5-4ad6-af77-b97c73a6b485 8
CXC chemokines IP-10 and Mig expression and direct migration of pulmonary CD8+/CXCR3+T cells in the lungs of patients with HIV infection and T-cell alveolitis, file e14fb267-90ee-3de1-e053-1705fe0ac030 8
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia, file e14fb267-a4fc-3de1-e053-1705fe0ac030 8
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial, file e14fb26e-ee3b-3de1-e053-1705fe0ac030 8
Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia, file e14fb26f-12de-3de1-e053-1705fe0ac030 8
Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment, file 740b5ad3-ee0f-49ee-85f6-dccc0c3de70c 7
Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience, file 986440d6-8481-456a-8d21-690f35017282 7
Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia, file e14fb268-fa8e-3de1-e053-1705fe0ac030 7
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab, file e14fb26d-56a7-3de1-e053-1705fe0ac030 7
HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen., file e14fb267-9f68-3de1-e053-1705fe0ac030 6
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity, file e14fb267-aa65-3de1-e053-1705fe0ac030 6
Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins, file e14fb268-9d8a-3de1-e053-1705fe0ac030 6
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia, file e14fb26e-f5c3-3de1-e053-1705fe0ac030 6
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real‐Life Campus CLL Study, file 1d074405-2d70-4d33-a979-caf9a5b10ef5 5
Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model, file 464269b4-b0c9-43f5-85d0-74c1d6241ff1 5
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma, file cd5f1876-bb2b-4db5-8024-55385fcaa4bc 5
Double autologous bone marrow transplantation and orthotopic liver transplantation in a patient with primary light chain (AL) amyloidosis, file e14fb267-98d6-3de1-e053-1705fe0ac030 5
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia., file e14fb267-a668-3de1-e053-1705fe0ac030 5
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome, file d7e4eb92-287a-4ae3-b665-be3507ac63fa 4
Multiple myeloma cell survival relies on high activity of protein kinase CK2, file e14fb267-879a-3de1-e053-1705fe0ac030 4
Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation., file e14fb267-8dcd-3de1-e053-1705fe0ac030 4
The chemokine receptor CXCR3 is expressed on malgnat B cells and mediates chemotaxis., file e14fb267-8ffd-3de1-e053-1705fe0ac030 4
Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes, file e14fb267-9569-3de1-e053-1705fe0ac030 4
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia, file e14fb267-9bf3-3de1-e053-1705fe0ac030 4
Cortactin, another player in the Lyn signaling pathway, is overexpressed and alternatively spliced in leukemic cells from patients with B-cell Chronic Lymphocytic Leukemia., file e14fb267-adb4-3de1-e053-1705fe0ac030 4
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL, file e14fb26f-dde3-3de1-e053-1705fe0ac030 4
A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection, file cc5f4ec7-9e9b-4eb1-b070-c9ae9bf08256 3
CXCR3 and its ligant CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection, file e14fb267-8fe0-3de1-e053-1705fe0ac030 3
Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas, file e14fb26e-5a6e-3de1-e053-1705fe0ac030 3
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study, file e14fb26e-815f-3de1-e053-1705fe0ac030 3
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia, file 0b3369ba-1329-4135-9e52-6b1c523f2fb4 2
CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis, file e14fb267-9b72-3de1-e053-1705fe0ac030 2
Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes, file e14fb267-9b9a-3de1-e053-1705fe0ac030 2
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study, file e14fb269-03af-3de1-e053-1705fe0ac030 2
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia, file e14fb270-0143-3de1-e053-1705fe0ac030 2
Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients, file 0ee031ad-8691-4bf1-a21f-86687218082a 1
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study, file 1815b0c6-4b1e-4aa0-b4fb-191ede8df460 1
Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients, file b6edb018-1503-4d9b-94c2-e48652d10424 1
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia., file e14fb267-8fc7-3de1-e053-1705fe0ac030 1
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease., file e14fb267-93b6-3de1-e053-1705fe0ac030 1
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations., file e14fb267-ad3b-3de1-e053-1705fe0ac030 1
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia., file e14fb267-adaf-3de1-e053-1705fe0ac030 1
Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A., file e14fb267-ae58-3de1-e053-1705fe0ac030 1
S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis., file e14fb268-3f0e-3de1-e053-1705fe0ac030 1
Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia, file e14fb268-fb50-3de1-e053-1705fe0ac030 1
Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy, file e14fb26e-73ce-3de1-e053-1705fe0ac030 1
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia, file e14fb26e-9799-3de1-e053-1705fe0ac030 1
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL, file e14fb26f-238a-3de1-e053-1705fe0ac030 1
Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature, file e14fb26f-dde8-3de1-e053-1705fe0ac030 1
Totale 2.107
Categoria #
all - tutte 7.768
article - articoli 7.726
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.494

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019117 0 0 0 0 0 0 0 2 11 25 43 36
2019/2020226 24 16 12 17 23 19 19 20 27 12 24 13
2020/2021375 23 15 18 16 8 16 17 50 45 107 39 21
2021/2022549 31 15 52 49 59 24 30 45 22 27 146 49
2022/2023543 37 40 118 84 43 70 24 28 16 15 59 9
2023/2024241 10 8 15 14 27 72 36 59 0 0 0 0
Totale 2.107